Dr. Lal Path Labs Ltd. — Q2 FY26 earnings call

Call held 31 Oct 2025

Management summary

Dr Lal Pathlabs delivered a resilient Q2 FY26 performance characterized by double-digit revenue growth and margin expansion despite a lower incidence of seasonal illnesses like Dengue and Malaria. Management demonstrated high confidence in the business model by announcing a 1:1 bonus issue and maintaining full-year growth guidance. The company is successfully pivoting toward higher-complexity testing and expanding its radiology pilot while maintaining a strong focus on the B2C segment.

Highlights

  • Revenue for Q2 FY26 grew 10.7% YoY to ₹731 crore, with H1 revenue reaching ₹1,400 crore (+11% YoY).

  • EBITDA margin for the quarter stood at 30.7% (₹224 crore), showing strong operational discipline.

  • PAT increased by 16.4% YoY to ₹152 crore in Q2, with a PAT margin of 20.8%.

  • Sample volume grew 10.3% to 25.4 million, while patient volume increased 5% to 8.2 million.

  • Revenue per patient improved by 5.4% YoY to ₹889, driven by better test mix and Swasthfit contribution.

  • The Board approved a 1:1 bonus issue of equity shares and an interim dividend of ₹7 per share (70%).

  • Flagship 'Swasthfit' program contributed 26% to Q2 revenues, serving as a key B2C growth driver.

  • Net cash position remains robust at ₹1,367 crore as of September 30, 2025.

Key financials

  1. Revenue ₹731 Cr +10.7%YoY
  2. EBITDA Margin 30.7%
  3. PAT ₹152 Cr +16.4%YoY
  4. EPS ₹18.1 +16.8%YoY
  5. Revenue per Patient ₹889 +5.4%YoY
  6. Sample Volume 25.4 Mn +10.3%YoY

What they filed

Q1 FY27: revenue up 19.2%, net profit up 28.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue631 569 577 641 700 +11%632 +11%675 +17%764 +19%
EBITDA194 151 159 183 215 +11%174 +15%182 +14%238 +30%
Net profit129 105 148 129 146 +13%92 −12%141 −5%166 +29%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Swasthfit (Bundled Packages)
    26% Revenue Contribution
  • B2C Business
    75% Revenue Contribution

Guidance & targets

Revenue

  • Annual Revenue Growth Revenue · FY26 · High confidence 11-12%

    From 11-12% today

    Binay, we had at the beginning of the year, guided a revenue growth range between 11% to 12% for this financial year, and we are staying with that number even as of now.

    — Shankha Banerjee, CEO

Margin

  • EBITDA Margin Band Margin · FY26 · Medium confidence 27-28%

    From 27-28% today

    So, yes, as earlier mentioned, this year, we are estimating that between 27% to 28% margins, we are confident to maintain.

    — Ved P Goel, Group CFO

Capex

  • Total Annual Capex Capex · FY26 · High confidence ₹130-140 crore
    So, overall about Rs. 130 crore, Rs. 140 crore CAPEX in this year is what we are estimating.

    — Ved P Goel, Group CFO

Capacity

  • New Lab Additions Capacity · FY26 · High confidence 15-20

    From 15-20 today

    I think beginning of the year itself, I had said 15 to 20 new labs is what we are looking at, and we are still guiding the same number.

    — Shankha Banerjee, CEO

  • New Collection Centers Capacity · FY26 · High confidence 600-800
    And in terms of collection center network, we should be maybe 600 to 800 number of new collection centers this financial year.

    — Shankha Banerjee, CEO

Risks & concerns

  • Seasonal Illness Volatility

    medium

    Lower incidence of Chikungunya, Malaria, and Dengue moderated overall volume growth compared to the previous year.

    Management acknowledged

  • Margin Compression in H2

    medium

    Investments and costs typically build up in the second half, which may dilute the high margins seen in Q2.

    Both acknowledged

  • Competitive Intensity

    medium

    Unorganized pathology sector remains the dominant player with high competitive intensity, though visible competition has become more rational.

    Management acknowledged

Areas of evasion (1)

  • Specific revenue contribution from the West region (stated they only give it once a year).

Q&A highlights

3 direct
Revenue Trajectory vs. Network Expansion Direct
I think one must understand that new network that one creates isn't going to be at a productivity level of existing network starting from day 1... It takes some time for networks to mature.

Explains why a 9% network expansion doesn't immediately translate to 15%+ revenue growth due to maturation cycles.

Asked by Binay Singh, Morgan Stanley

Pricing Strategy and GST Benefits Direct
I don't think in this year, this price increase is on the cards, because another development on account of GST... we have to pass on this benefit to the customer.

Management clarified that organic growth is the priority and price hikes are unlikely in the near term as they pass through tax savings to remain competitive.

Asked by Anshul Agrawal, Emkay Global

Radiology Pilot and Expansion Direct
We have decided to expand that pilot into a few more centers... those investments are also likely to happen in this financial year.

Signals a strategic move into high-end radiology (CT/MRI), which could significantly increase ARPP (Average Revenue Per Patient) in the long term.

Asked by Rishi Modi, Individual Investor

2 min read 5 chapters

Detailed narrative

Resilient Volume Growth Amidst Seasonal Headwinds

Dr Lal Pathlabs recorded a 10.7% YoY revenue growth in Q2 FY26, reaching ₹731 crore. This was supported by a 10.3% increase in sample volumes to 25.4 million and a 5% rise in patient volumes to 8.2 million. Management noted that while core growth was strong, overall volumes were moderated by a lower incidence of seasonal illnesses like Dengue and Malaria compared to the previous year. Despite this, revenue per patient improved by 5.4% to ₹889, reflecting a better test mix and the success of the Swasthfit program.

Strategic Expansion into Radiology and High-End Testing

The company is successfully piloting high-end radiology services (CT and MRI) in Delhi NCR and plans to expand this to more centers within the current financial year. Management indicated that the investment for these centers is lower than the industry average of ₹20-25 crore because they are leveraging existing infrastructure. Additionally, the Genevolve division is enhancing capabilities in molecular diagnostics and personalized medicine, while the integration of AI modules for cancer detection underscores their leadership in new-age diagnostics.

Margin Sustainability and Investment Outlook

Q2 EBITDA margins were robust at 30.7%, though management maintained a full-year guidance of 27-28% to account for planned investments in the second half. Total CAPEX for FY26 is estimated at ₹130-140 crore, which includes ₹75 crore for property acquisition in Shalimar Bagh to enhance super-specialty testing capabilities. The company is also passing on GST benefits from reduced rates on reagents to customers, which precludes immediate price hikes but supports organic volume growth.

Network Maturation and Regional Focus

Management emphasized that new network points take time to reach the productivity levels of established labs. They are maintaining a disciplined cluster-based expansion, with a renewed focus on Delhi NCR, which has responded with double-digit growth. The company plans to add 15-20 new labs and 600-800 collection centers in FY26. The Suburban IT integration in the West is now complete, with management expecting a return to double-digit growth in that geography by Q4 FY26.

Strong Shareholder Returns and Cash Position

Reflecting strong operational performance and a healthy cash balance of ₹1,367 crore, the Board approved a 1:1 bonus issue and an interim dividend of ₹7 per share. Management stated that their B2C contribution remains high at approximately 75% of total revenue, and they are not actively seeking to increase this ratio further, viewing it as a 'reasonably good' level. The focus remains on driving sustainable, long-term growth through geographic expansion and portfolio innovation.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls